한글목차

올리고뉴클레오티드 요법 시장 규모는 최근 급성장하고 있습니다. 2025년 62억 달러에서 2026년에는 69억 1,000만 달러에 이르고, CAGR 11.5%의 성장이 전망되고 있습니다. 지난 수년간의 성장에는 올리고뉴클레오티드 합성 연구 개발 증가, 표적치료제에 대한 수요 증가, 분자생물학 기술의 발전, 만성질환 및 유전성 질환 증가, 안티센스 및 압타머 기술의 조기 도입 등이 주요 요인으로 꼽힙니다.

향후 몇 년간 올리고뉴클레오티드 요법 시장 규모는 급성장이 전망됩니다. 2030년에는 12.0%의 연평균 복합 성장률(CAGR)로 108억 7,000만 달러에 이를 전망입니다. 예측 기간의 성장 요인으로는 개인 맞춤형 의료의 확대, 신약개발에 인공지능(AI)의 통합, 정밀의료 이니셔티브의 발전, 차세대 전달 플랫폼의 개발, 바이오텍과 제약사간의 제휴 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 표적 유전자 조절, RNA 간섭(RNAi) 기반 치료법, 개인 맞춤형 의료 개발, 첨단 약물 전달 시스템, 핵산 기반 진단 기술 등이 있습니다.

의료 분야의 연구개발을 지원하는 정부의 이니셔티브는 올리고뉴클레오타이드 치료 시장의 성장을 가속할 것으로 예측됩니다. 이러한 노력에는 특정 의료 문제에 대응하고, 목표를 달성하고, 사회 변화를 촉진하기 위해 지역, 지역, 국가 및 국제 수준에서 정부 기관이 시행하는 프로그램, 정책 및 프로젝트가 포함됩니다. 여러 정부에서 올리고뉴클레오타이드 치료의 다양한 측면을 지원하는 정책을 시행하고 있습니다. 예를 들어, 미국의 전문 기관인 미국 의사협회(AMA)에 따르면, 2025년 4월 기준 2023년 미국의 의료비 지출은 전년 대비 7.5% 증가한 4조 9,000억 달러(1인당 1만 4,570달러)에 달하고, 2022년 4.6% 증가율을 상회할 것으로 예상했습니다. 이처럼 정부 주도의 의료 연구개발에 대한 투자가 올리고뉴클레오타이드 치료제 시장의 성장을 견인하고 있습니다.

올리고뉴클레오타이드 치료제 시장의 주요 기업들은 유전자 치료와 같은 첨단 치료법을 개발하여 유전성 질환의 근본 원인에 접근하고, 환자 치료 결과를 개선하며, 장기적인 치료 부담을 줄이는 것을 목표로 하고 있습니다. 유전자 치료는 기능장애나 변이된 유전자를 대체하기 위해 환자의 세포에 기능적인 유전자를 도입하는 치료법입니다. 예를 들어, 2023년 6월 미국 소재 바이오테크 기업 Sarepta Therapeutics Inc.는 세계 최초로 듀센형 근이영양증(DMD) 보행이 가능한 소아 환자를 대상으로 한 유전자 치료제 'ELEVIDYS'에 대한 FDA 승인을 FDA 승인을 획득하였습니다. 이 단회 투여 치료는 단축된 기능성 디스트로핀을 암호화하는 유전자를 근육 세포에 도입하여 질환의 진행을 막거나 역전시키는 것을 목표로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Oligonucleotide therapy is a term for advanced molecular-targeting treatments that use chemically synthesized oligonucleotides with single-stranded DNA or RNA backbones, offering high selectivity. Oligonucleotides are designed to base-pair with specific DNA or RNA strands for most applications, with PCR primers being the most common use of oligonucleotides (polymerase chain reaction).

The main types of oligonucleotide therapy include antisense oligonucleotides, aptamers, and others. Antisense oligonucleotides (ASOs) are synthetic DNA oligomers that bind to a target RNA in a sequence-specific manner. They are used to inhibit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. Oligonucleotide therapies are applied in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and other conditions, and are utilized in hospitals and research institutes.

Tariffs have affected the oligonucleotide therapy market by increasing costs of imported nucleotides, reagents, and specialized synthesis equipment, causing delays in production and supply chains. The impact is particularly notable in segments such as antisense oligonucleotides and aptamers, with North America, Europe, and Asia-Pacific being most affected due to high import dependencies. Some positive impacts include incentivizing local manufacturing and fostering innovation in cost-effective oligonucleotide synthesis and delivery solutions.

The oligonucleotide therapy market research report is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market statistics, including oligonucleotide therapy industry global market size, regional shares, competitors with a oligonucleotide therapy market share, detailed oligonucleotide therapy market segments, market trends and opportunities, and any further data you may need to thrive in the oligonucleotide therapy industry. This oligonucleotide therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oligonucleotide therapy market size has grown rapidly in recent years. It will grow from $6.2 billion in 2025 to $6.91 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to increasing r&d in oligonucleotide synthesis, growing demand for targeted therapies, advances in molecular biology techniques, rise in chronic and genetic diseases, early adoption of antisense and aptamer technologies.

The oligonucleotide therapy market size is expected to see rapid growth in the next few years. It will grow to $10.87 billion in 2030 at a compound annual growth rate (CAGR) of 12.0%. The growth in the forecast period can be attributed to expansion of personalized medicine, integration of ai in drug discovery, growth of precision medicine initiatives, development of next-gen delivery platforms, increasing partnerships between biotech and pharma companies. Major trends in the forecast period include targeted gene regulation, rna interference-based therapeutics, personalized medicine development, advanced drug delivery systems, nucleic acid-based diagnostics.

Government initiatives supporting research and development in healthcare are expected to drive growth in the oligonucleotide therapy market. Such initiatives encompass programs, policies, and projects undertaken by government authorities at local, regional, national, or international levels to address specific healthcare challenges, achieve objectives, and promote positive societal change. Several governments are implementing initiatives that support various aspects of oligonucleotide therapy. For instance, in April 2025, according to the American Medical Association, a US-based professional organization, U.S. health spending in 2023 rose by 7.5% to $4.9 trillion, or $14,570 per capita, surpassing the 4.6% increase seen in 2022. These government-led investments in healthcare research and development are therefore driving growth in the oligonucleotide therapy market.

Leading companies in the oligonucleotide therapy market are developing advanced treatments, such as gene therapies, to target the root causes of genetic diseases, improve patient outcomes, and reduce long-term treatment burdens. Gene therapies involve introducing a functional gene into a patient's cells to replace a non-functional or mutated gene. For example, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for ELEVIDYS, a first-of-its-kind gene therapy for ambulatory pediatric patients with Duchenne muscular dystrophy (DMD). This single-dose treatment delivers a gene coding for a shortened functional form of dystrophin to muscle cells, aiming to halt or reverse disease progression.

In April 2025, AlphaRose Therapeutics, a US-based biopharmaceutical company, acquired Alpha Anomeric SA for an undisclosed amount. This acquisition enables AlphaRose Therapeutics to strengthen its oligonucleotide therapeutics portfolio, accelerate innovation in gene-targeted therapies, expand R&D capabilities, and enhance its competitive position in the global nucleic acid therapeutics market. Alpha Anomeric SA is a France-based company specializing in oligonucleotide therapies.

Major companies operating in the oligonucleotide therapy market are Pfizer Inc., GlaxoSmithKline plc, Gilead Sciences Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V., Evox Therapeutics Ltd., PepGen Ltd.

North America was the largest region in the oligonucleotide therapy market in 2025. The regions covered in the oligonucleotide therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oligonucleotide therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oligonucleotide therapy market consists of sales of ASOs, siRNAs, miRNAs, and DNAzymes. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oligonucleotide Therapy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oligonucleotide therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oligonucleotide therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Antisense Oligonucleotide; Aptamer; Other Types
• 2) By Application: Infectious Diseases; Oncology; Neurodegenerative Disorders; Cardiovascular Diseases; Kidney Diseases; Other End-User
• 3) By End User: Hospitals; Research Institutes
• Subsegments:
• 1) By Antisense Oligonucleotide: RNA-Targeted Antisense Oligonucleotides; DNA-Targeted Antisense Oligonucleotides; Chemically Modified Antisense Oligonucleotides
• 2) By Aptamer: DNA Aptamers; RNA Aptamers; Small Molecule Aptamers
• 3) By Other Types: siRNA (Small Interfering RNA); miRNA (Micro RNA); DNAzyme And Ribozymes; Synthetic Oligonucleotides For Gene Editing
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Gilead Sciences Inc.; Biogen Inc.; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Akcea Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; SomaGenics Inc.; Wave Life Sciences Ltd.; Exicure Inc.; Avidity Biosciences Inc.; Miragen Therapeutics Inc.; ProQR Therapeutics NV; Regulus Therapeutics Inc.; Kastle Therapeutics LLC; Santaris Pharma A/S; InteRNA Technologies B.V.; Evox Therapeutics Ltd.; PepGen Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Oligonucleotide Therapy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Oligonucleotide Therapy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Oligonucleotide Therapy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Oligonucleotide Therapy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Targeted Gene Regulation
  • 4.2.2 Rna Interference-Based Therapeutics
  • 4.2.3 Personalized Medicine Development
  • 4.2.4 Advanced Drug Delivery Systems
  • 4.2.5 Nucleic Acid-Based Diagnostics

5. Oligonucleotide Therapy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Research Institutes
• 5.3 Pharmaceutical Companies
• 5.4 Biotechnology Firms
• 5.5 Academic Institutions

6. Oligonucleotide Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oligonucleotide Therapy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Oligonucleotide Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Oligonucleotide Therapy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Oligonucleotide Therapy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Oligonucleotide Therapy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oligonucleotide Therapy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oligonucleotide Therapy Market Segmentation

• 9.1. Global Oligonucleotide Therapy Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antisense Oligonucleotide, Aptamer, Other Types
• 9.2. Global Oligonucleotide Therapy Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Other End-User
• 9.3. Global Oligonucleotide Therapy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Research Institutes
• 9.4. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• RNA-Targeted Antisense Oligonucleotides, DNA-Targeted Antisense Oligonucleotides, Chemically Modified Antisense Oligonucleotides
• 9.5. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Aptamer, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• DNA Aptamers, RNA Aptamers, Small Molecule Aptamers
• 9.6. Global Oligonucleotide Therapy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• siRNA (Small Interfering RNA), miRNA (Micro RNA), DNAzyme And Ribozymes, Synthetic Oligonucleotides For Gene Editing

10. Oligonucleotide Therapy Market Regional And Country Analysis

• 10.1. Global Oligonucleotide Therapy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Oligonucleotide Therapy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oligonucleotide Therapy Market

• 11.1. Asia-Pacific Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oligonucleotide Therapy Market

• 12.1. China Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oligonucleotide Therapy Market

• 13.1. India Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oligonucleotide Therapy Market

• 14.1. Japan Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oligonucleotide Therapy Market

• 15.1. Australia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oligonucleotide Therapy Market

• 16.1. Indonesia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oligonucleotide Therapy Market

• 17.1. South Korea Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oligonucleotide Therapy Market

• 18.1. Taiwan Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oligonucleotide Therapy Market

• 19.1. South East Asia Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oligonucleotide Therapy Market

• 20.1. Western Europe Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oligonucleotide Therapy Market

• 21.1. UK Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oligonucleotide Therapy Market

• 22.1. Germany Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oligonucleotide Therapy Market

• 23.1. France Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oligonucleotide Therapy Market

• 24.1. Italy Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oligonucleotide Therapy Market

• 25.1. Spain Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oligonucleotide Therapy Market

• 26.1. Eastern Europe Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oligonucleotide Therapy Market

• 27.1. Russia Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oligonucleotide Therapy Market

• 28.1. North America Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oligonucleotide Therapy Market

• 29.1. USA Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oligonucleotide Therapy Market

• 30.1. Canada Oligonucleotide Therapy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oligonucleotide Therapy Market

• 31.1. South America Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oligonucleotide Therapy Market

• 32.1. Brazil Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oligonucleotide Therapy Market

• 33.1. Middle East Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oligonucleotide Therapy Market

• 34.1. Africa Oligonucleotide Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Oligonucleotide Therapy Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oligonucleotide Therapy Market Regulatory and Investment Landscape

36. Oligonucleotide Therapy Market Competitive Landscape And Company Profiles

• 36.1. Oligonucleotide Therapy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Oligonucleotide Therapy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Oligonucleotide Therapy Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Oligonucleotide Therapy Market Other Major And Innovative Companies

• Sarepta Therapeutics Inc., Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SomaGenics Inc., Wave Life Sciences Ltd., Exicure Inc., Avidity Biosciences Inc., Miragen Therapeutics Inc., ProQR Therapeutics NV, Regulus Therapeutics Inc., Kastle Therapeutics LLC, Santaris Pharma A/S, InteRNA Technologies B.V.

38. Global Oligonucleotide Therapy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oligonucleotide Therapy Market

40. Oligonucleotide Therapy Market High Potential Countries, Segments and Strategies

• 40.1 Oligonucleotide Therapy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Oligonucleotide Therapy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Oligonucleotide Therapy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer